INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic degenerative disease that is associated with a progressive and accelerated reduction in the patients lung function. The reduction of the lung function is frequently accompanied by a worsening dyspnea, and by episodes of acute worsening of symptoms that require specific drug treatment and, in many cases emergency or hospital care. Such exacerbations (acute worsening of symptoms) are associated with a poor prognosis in terms of accelerated lung function decline (1,2) and with increased risk of death (3, 4) . COPD exacerbations are also associated with reduced physical activity and poor health status (5−7) Prevention of exacerbations is an a key component of any management strategy for COPD (8) and a key objective for new pharmacologic treatments for COPD.
Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) have shown efficacy in preventing exacerbations in patients with COPD (9-13). Though these agents have proven to be effective in the treatment of COPD, deterioration in the patient health status can persist and therefore there is a need for increased disease control.
In the SPARK trial, dual bronchodilation with QVA149 demonstrated advantages in reducing the risk of COPD exacerbations in severe and very severe patients when compared to single bronchodilation therapy (14) and was associated to concomitant improvements in lung function and health status (14).
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METHODOLOGY
A cost-consequence model was developed using the SPARK study data to derive treatment outcomes for QVA149 and tiotropium. Primary outcomes of interest were COPD exacerbations (moderate or severe) and direct cost for the Portuguese NHS.
Target population
Patients with COPD that are at risk of exacerbation, defined as patients with severe to very severe airflow limitation and documented history of at least one exacerbation in the previous 12 months (GOLD C and GOLD D) and who are therefore at high risk of future adverse outcomes and eligible for dual bronchodilation with QVA149.
Outcomes of interest
The analysis considered the impact on prevention of COPD exacerbations (total, mild and moderate or severe) and direct costs for the Portuguese NHS (table 1) .
Clinical inputs
The model was populated with data from the SPARK study (table 2) a parallel-group study that enrolled 2,224 patients with COPD (aged ≥40 years, GOLD stages III-IV, and one or more moderate COPD exacerbation in the past year) and assessed the efficacy of once-daily QVA149 (fixed-dose combination of indacaterol 110 μg and glycopyrronium 50 μg) once-daily glycopyrronium (50 μg) and tiotropium (18 μg) for 64 weeks.
Study perspective and time horizon
The analysis assumed a 1 year time horizon (365 days) and the perspective of the Portuguese NHS.
Costs
Drug acquisition costs were estimated assuming the recommended (SmPC approved) dose, frequency of administration and official list price (table 3) . It was estimated the daily treatment cost for QVA149 (indacaterol/glycopirronium 110/50 µd once a day) and tiotropium (18 µg once a day). Costs associated with the treatment of a moderate or severe exacerbation were estimated as cost per event treated and based in previously published analysis (16). In this study it was assumed a cost of treating an exacerbation for a GOLD III/IV patient including costs with hospitalization (table 3) . Alternative scenarios were analyses to identify the impact of this assumption. For mild exacerbations no cost was considered since in the SPARK study it was assumed that mild interventions were self-managed by the patient without additional health care resource use.
OBJECTIVE
Estimate the clinical benefits and the budget impact associated with the use of QVA149 (indacaterol 110 μg/glycopyrronium 50 μg) instead of tiotropium (18 μ), in severe and very severe COPD patients in Portugal. 
RESULTS

It is estimated that
CONCLUSION
Symptom control in COPD is essential and evidence shows that dual bronchodilation with QVA149 brings benefits when compared to tiotropium. The use of QVA149 in symptomatic patients instead tiotropium may improve treatment outcomes and reduce overall costs for the Portuguese NHS. When compared to tiotropium, is expected that the population treated with QVA149 will experience less moderate to severe exacerbations and will reduce significantly the need for additional healthcare resource use.
The impact on the patients quality of life was not analyzed in this study so we might be undervaluing the real benefits associated to the use of QVA 149 in this population.
The scenario analysis also shows that the potential gains in health outcomes (less moderate to severe exacerbations vs. tiotropium) can be maximized if a larger population of GOLD C and D patients are treated with QVA 149 without increasing the overall costs for the Portuguese NHS. Exacerbation was defined as the presence of two major symptoms (dyspnoea, sputum volume, sputum purulence) for at least 2 consecutive days or a worsening of one major symptom together with an increase in any one minor symptom (sore throat, colds, fever without other cause, cough, wheeze) for at least 2 consecutive days. After 1 year, it is estimated that the 2,304 patients experience a total of 9,262 exacerbations with 2,143 moderate to severe exacerbations. If the same population was treated with QVA 149 it is estimated that they will experience 7.926 exacerbations with 1.935 moderate to severe exacerbations ( Figure  2 ). The QVA149 cohort will experience less -1.336 exacerbations, with less -208 moderate to severe exacerbations (Figure 2 ) 
Scenario analysis
• Scenario 1: It is expected that the 11.293 patients treated with tiotropium (18 µg) experience a total of 45.398 exacerbations, with 10.502 moderate to severe. If treated with QVA 149 it is expected that the same population will experience a total of 38.848 exacerbations (less 6.550 than the tiotropium patients), with 9.486 moderate to severe (less 1.016 than the tiotropium patients). Treating the patients with QVA 149 was associated with less overall costs, -€63.760 wen compared to the tiotropium group.
• Scenario 2: Assuming the weighted average cost described in Reis N (16) the overall treatment costs for the tiotropium group will amount to €6.542.179, with €5.398.474 in moderate to severe exacerbation treatment costs. The overall treatment costs in the QVA 149 treatment group will amount to €6.640.513, with €4.874.497 in moderate to severe exacerbation treatment costs.
Alternative scenarios were tested:
• Scenario 1: Considering that the total GOLD C and D population treated with Tiotropium would be treated with QVA149.
• Scenario 2: Considering the information described by Reis N (16) in her research were 71% of the COPD patients analyzed (all GOLD stages) registered an exacerbation. From the patients that registered exacerbations 43% required hospitalization. The weighted average costs identified for an exacerbation in this population was €2.519,12 (cost for all GOLD stages); 
